WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal first quarter of 2015 ended March 31, 2015.
“Interleukin Genetics’ highest priority in the coming months is to maximize the commercial potential of PerioPredict®, our genetics-based risk assessment test for severe periodontitis,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.
Help employers find you! Check out all the jobs and post your resume.
“Interleukin Genetics’ highest priority in the coming months is to maximize the commercial potential of PerioPredict®, our genetics-based risk assessment test for severe periodontitis,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.
Help employers find you! Check out all the jobs and post your resume.
